Clinical Trials

The clinical trial landscape for Allyl Methyl Sulfide includes a clinical trial sponsored by a public research institution, the USDA Beltsville Human Nutrition Research Center. This study evaluated physiological conditions focused on the systemic absorption of garlic metabolites under a protocol assigned a trial phase of Not Applicable. Regarding recruitment status, the study was officially listed as withdrawn, terminating active enrollment prior to completion.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02322541 Withdrawn
Focus is Understanding Absorption of Garlic Metabolites
USDA Beltsville Human Nutrition Research Center
2016-09 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Allyl Methyl Sulfide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Allyl Methyl Sulfide binds key intracellular targets to disrupt downstream biochemical pathways, modulating oxidative stress dynamics and altering cell survival signaling. This cellular modulation promotes antiproliferative and antimicrobial activities, providing a biological rationale for clinical studies aimed at understanding the systemic absorption and metabolism of garlic-derived organosulfur compounds.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.